Coloplast A/S (CPH:COLOB), a medical device and related services company, reported on Tuesday net profit of DKK991m, or EPS of DKK4.66, for the first quarter of 2018/19, from 1 October 2018 to 31 December 2018.

This was a 5% increase over net profit of DKK940m, or EPS of DKK4.42, in Q1 2017/18.

Revenues for the quarter were DKK4,321m, up by 9% as compared with DKK3,955m in Q1 of 2017/18. Organic growth in the quarter was 8%.

Organic growth rates in the business areas for the quarter were 8% in Ostomy Care, 8%, in Continence Care, 9% in Interventional Urology and 11% in Wound & Skin Care 11%.

Also, there was solid growth during the quarter across all geographical regions, in particular Europe with 6% organic growth, driven by new product launches including SenSura Mio Convex and SpeediCath Flex.

In addition, the company provided financial guidance for 2018/19 and continues to expect organic revenue growth of 8% at constant exchange rates and a reported growth in DKK of 8% to 9%.

Further, Coloplast has expands its SpeediCath portfolio with the launch of SpeediCath Navi, a hydrophilic catheter specifically designed for emerging markets. This product will be launched during 2019 and 2020.

Coloplast A/S is a Danish multinational company that develops, manufactures and markets medical devices and services related to ostomy, urology, continence, and wound care.

(EUR1.00=DKK7.46)